Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,840 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-world comparative study of the efficacy of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study.
Hayashi S, Tachibana S, Maeda T, Yamashita M, Shirasugi I, Yamamoto Y, Yamada H, Okano T, Nishimura K, Ueda Y, Jinnno S, Saegusa J, Yamamoto W, Murata K, Fujii T, Hata K, Yoshikawa A, Ebina K, Etani Y, Yoshida N, Amuro H, Hashimoto M, Hara R, Katayama M, Okano T, Kuroda R. Hayashi S, et al. Among authors: hata k. Rheumatology (Oxford). 2023 Nov 1:kead543. doi: 10.1093/rheumatology/kead543. Online ahead of print. Rheumatology (Oxford). 2023. PMID: 37924201
Comparison of efficacy between anti-IL-6 receptor antibody and other biological disease-modifying antirheumatic drugs in the patients with rheumatoid arthritis who have knee joint involvement: the ANSWER cohort, retrospective study.
Maeda Y, Hirano T, Ebina K, Hara R, Hashimoto M, Yamamoto W, Murakami K, Kotani T, Hata K, Son Y, Amuro H, Onishi A, Jinno S, Katayama M, Kumanogoh A. Maeda Y, et al. Among authors: hata k. Rheumatol Int. 2021 Jul;41(7):1233-1241. doi: 10.1007/s00296-021-04862-y. Epub 2021 Apr 26. Rheumatol Int. 2021. PMID: 33903963
Favorable clinical response and drug retention of anti-IL-6 receptor inhibitor in rheumatoid arthritis with high CRP levels: the ANSWER cohort study.
Nakayama Y, Hashimoto M, Watanabe R, Murakami K, Murata K, Tanaka M, Ito H, Yamamoto W, Ebina K, Hata K, Hiramatsu Y, Katayama M, Son Y, Amuro H, Akashi K, Onishi A, Hara R, Yamamoto K, Ohmura K, Matsuda S, Morinobu A. Nakayama Y, et al. Among authors: hata k. Scand J Rheumatol. 2022 Nov;51(6):431-440. doi: 10.1080/03009742.2021.1947005. Epub 2021 Sep 13. Scand J Rheumatol. 2022. PMID: 34511031
Prognostic factors affecting respiratory-related death in patients with rheumatoid arthritis complicated by interstitial lung disease: An ANSWER cohort study.
Makino H, Kotani T, Hata K, Nishioka D, Yamamoto W, Yoshikawa A, Wada Y, Hiramatsu Y, Shiba H, Nagai K, Katayama M, Son Y, Amuro H, Onishi A, Akashi K, Hara R, Hirano T, Hashimoto M, Takeuchi T. Makino H, et al. Among authors: hata k. Mod Rheumatol. 2023 Aug 25;33(5):928-935. doi: 10.1093/mr/roac115. Mod Rheumatol. 2023. PMID: 36112486
Prognostic Factors Affecting Death in Patients with Rheumatoid Arthritis Complicated by Pneumocystis jirovecii Pneumonia and One-Year Clinical Course: The ANSWER Cohort Study.
Shiba H, Kotani T, Nagai K, Hata K, Yamamoto W, Yoshikawa A, Wada Y, Hiramatsu Y, Makino H, Ueda Y, Onishi A, Murata K, Amuro H, Son Y, Hara R, Hirano T, Ebina K, Katayama M, Hashimoto M, Takeuchi T. Shiba H, et al. Among authors: hata k. Int J Mol Sci. 2023 Apr 17;24(8):7399. doi: 10.3390/ijms24087399. Int J Mol Sci. 2023. PMID: 37108561 Free PMC article.
Comparative effectiveness of biological disease-modifying antirheumatic drugs and Janus kinase inhibitor monotherapy in rheumatoid arthritis.
Onishi A, Yamada H, Yamamoto W, Watanabe R, Hara R, Katayama M, Okita Y, Maeda Y, Amuro H, Son Y, Yoshikawa A, Hata K, Hashimoto M, Saegusa J, Morinobu A. Onishi A, et al. Among authors: hata k. Rheumatology (Oxford). 2023 Nov 21:kead620. doi: 10.1093/rheumatology/kead620. Online ahead of print. Rheumatology (Oxford). 2023. PMID: 37988163
1,840 results